Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Eric Paul Winer, M.D.

Co-Author

This page shows the publications co-authored by Eric Winer and Jennifer Ligibel.
Connection Strength

5.681
  1. Ligibel JA, Giobbie-Hurder A, Shockro L, Campbell N, Partridge AH, Tolaney SM, Lin NU, Winer EP. Randomized trial of a physical activity intervention in women with metastatic breast cancer. Cancer. 2016 Apr 15; 122(8):1169-77.
    View in: PubMed
    Score: 0.727
  2. Ligibel JA, Winer EP. Aromatase inhibition in obese women: how much is enough? J Clin Oncol. 2012 Aug 20; 30(24):2940-2.
    View in: PubMed
    Score: 0.567
  3. Ligibel JA, Partridge A, Giobbie-Hurder A, Campbell N, Shockro L, Salinardi T, Salinardri T, Winer EP. Physical and psychological outcomes among women in a telephone-based exercise intervention during adjuvant therapy for early stage breast cancer. J Womens Health (Larchmt). 2010 Aug; 19(8):1553-9.
    View in: PubMed
    Score: 0.495
  4. Ligibel JA, Partridge A, Giobbie-Hurder A, Golshan M, Emmons K, Winer EP. Physical activity behaviors in women with newly diagnosed ductal carcinoma-in-situ. Ann Surg Oncol. 2009 Jan; 16(1):106-12.
    View in: PubMed
    Score: 0.438
  5. Ligibel JA, Campbell N, Partridge A, Chen WY, Salinardi T, Chen H, Adloff K, Keshaviah A, Winer EP. Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol. 2008 Feb 20; 26(6):907-12.
    View in: PubMed
    Score: 0.418
  6. Ligibel JA, Winer EP. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early stage breast cancer. Womens Health (Lond). 2006 Jan; 2(1):89-97.
    View in: PubMed
    Score: 0.360
  7. Ligibel JA, Winer EP. Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions. Breast Cancer Res. 2005; 7(6):255-7.
    View in: PubMed
    Score: 0.357
  8. Ligibel JA, Winer EP. The aromatase inhibitors as adjuvant therapy for hormone receptor-positive breast cancer. J Natl Compr Canc Netw. 2003 Apr; 1(2):215-21.
    View in: PubMed
    Score: 0.298
  9. Ligibel JA, Winer EP. Clinical differences among the aromatase inhibitors. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):473S-9S.
    View in: PubMed
    Score: 0.293
  10. Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol. 2002 Jun; 29(3 Suppl 11):38-43.
    View in: PubMed
    Score: 0.281
  11. Ligibel JA, Barry WT, Alfano C, Hershman DL, Irwin M, Neuhouser M, Thomson CA, Delahanty L, Frank E, Spears P, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hahn O, Hudis C, Winer EP, Wadden TA, Goodwin PJ. Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. NPJ Breast Cancer. 2017; 3:37.
    View in: PubMed
    Score: 0.203
  12. Ligibel JA, Winer E, Hudis CA, Barry WT. Response. J Natl Cancer Inst. 2016 Jan; 108(1).
    View in: PubMed
    Score: 0.180
  13. Ligibel JA, Winer E, Hudis CA, Barry WT. Response. J Natl Cancer Inst. 2015 Jan; 108(1).
    View in: PubMed
    Score: 0.178
  14. Ligibel JA, Cirrincione CT, Liu M, Citron M, Ingle JN, Gradishar W, Martino S, Sikov W, Michaelson R, Mardis E, Perou CM, Ellis M, Winer E, Hudis CA, Berry D, Barry WT. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). J Natl Cancer Inst. 2015 Sep; 107(9).
    View in: PubMed
    Score: 0.174
  15. Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, Macdonald SM, Mahadevan A, Eisenberg E, Ligibel JA, Mayer EL, Moy B, Eichler AF, Winer EP. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat. 2013 Nov; 142(2):405-14.
    View in: PubMed
    Score: 0.155
  16. Ligibel JA, O'Malley AJ, Fisher M, Daniel GW, Winer EP, Keating NL. Patterns of bone density evaluation in a community population treated with aromatase inhibitors. Breast Cancer Res Treat. 2012 Aug; 134(3):1305-13.
    View in: PubMed
    Score: 0.142
  17. Ligibel JA, James O'Malley A, Fisher M, Daniel GW, Winer EP, Keating NL. Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients. Breast Cancer Res Treat. 2012 Jan; 131(2):589-97.
    View in: PubMed
    Score: 0.133
  18. Ligibel JA, Giobbie-Hurder A, Olenczuk D, Campbell N, Salinardi T, Winer EP, Mantzoros CS. Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors. Cancer Causes Control. 2009 Oct; 20(8):1523-8.
    View in: PubMed
    Score: 0.114
  19. Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K, Winer E. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst. 2008 Feb 20; 100(4):243-51.
    View in: PubMed
    Score: 0.104
  20. Freedman RA, Bullitt E, Sun L, Gelman R, Harris G, Ligibel JA, Krop IE, Partridge AH, Eisenberg E, Winer EP, Lin NU. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer. 2011 Dec; 11(6):376-83.
    View in: PubMed
    Score: 0.033
  21. de Moor JS, Partridge AH, Winer EP, Ligibel J, Emmons KM. The role of socioeconomic status in adjustment after ductal carcinoma in situ. Cancer. 2010 Mar 01; 116(5):1218-25.
    View in: PubMed
    Score: 0.030
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.